Market Overview

Stocks Hitting 52-Week Highs

Related MDVN
New Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 American Society of Clinical Oncology Annual Meeting
3 Biotech Stocks With Rising Short Interest
After Hours Gainers / Losers (Seeking Alpha)
Related TEVA
Mylan Sends Letter to Teva CEO
Teva Announces Exclusive Launch of Generic Actonel Tablets in the United States
Wall Street Breakfast: Greek Debt Deal Talks Intensify (Seeking Alpha)

Medivation (NASDAQ: MDVN) shares touched a new 52-week high of $86.54 after the company and Astellas reported final results from the Phase 3 PREVAIL trial of Enzalutamide. Credit Suisse lifted the price target on Medivation from $80.00 to $95.00.

Teva Pharmaceutical Industries (NYSE: TEVA) shares reached a new 52-week high of $45.60 after the company reported the FDA approval of three-times-a-week COPAXONE 40mg/mL.

CBRE Group (NYSE: CBG) shares jumped 1.54% to touch a new 52-week high of $27.06. CBRE Group is expected release its Q4 financial results on February 5, 2014.

Jones Lang LaSalle (NYSE: JLL) shares surged 5.69% to reach a new 52-week high of $112.36 after the company reported stronger-than-expected Q4 results.

Posted-In: 52-Week HighsNews Intraday Update Markets Movers


Related Articles (CBG + JLL)

Around the Web, We're Loving...

Get Benzinga's Newsletters